Efficacy and Safety of HIV Vaccine 732462 in ART-naïve HIV-1 Infected Persons
Phase of Trial: Phase II
Latest Information Update: 29 May 2018
At a glance
- Drugs GSK 732461 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Dec 2011 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.